InnoMed Technologies/Mergenet Solutions Accept 170th and 171st Medical Advisory Board Members

Tuesday, April 15, 2003

BOCA RATON, Fla.--(BUSINESS WIRE)-- Innomed Technologies, Inc., a Boca Raton, Florida-based medical technology company for the respiratory and sleep apnea markets and its parent company, Mergenet Solutions, accepted their 170th and 171st Idea Forum Medical Advisory board members. (The Idea Forum is composed of a medical board, an energy board and a technical board.) Innomed Technologies launched the FDA-approved Nasal Aire(R) interface, which may revolutionize the sleep apnea industry, last January.

The newest medical board members to the Idea Forum are Akshay Mahadevia, M.D., a sleep specialist and Pulmonologist in Davenport, Iowa, one of the first innovators of CPAP use in pulmonology; and Lee Brooks, M.D., Pediatric Pulmonary Specialist, Children's Hospital of Philadelphia.

"I'm excited about the company and about the Nasal Aire(R) interface, which I use frequently in my practice," said Dr. Mahadevia. "As a pulmonologist and sleep specialist, I have found the Nasal Aire to be much more comfortable than other CPAPs for patients and the feedback has been excellent."

Independent clinical trials were conducted last year for the Nasal Aire(R), which showed that when patients are given a choice between using the Nasal Aire(R) or the three leading competitive masks, manufactured by Resmed, Inc. (NYSE:RMD), Respironics (Nasdaq:RESP), and Mallinckrodt , 98% of the time the Nasal Aire(R) was chosen.

"I am delighted to serve as a member of the Idea Forum Medical Board, enabling me to contribute to innovative companies like Innomed Technologies and Mergenet Solutions," said Bob Coli, M.D., a specialist based in Warrick, RI, and an Idea Forum member since June 2000. "Contributing to the process of educating physicians and consumers about revolutionary medical products like the new Nasal Aire(R) interface, is extremely gratifying."

Kenneth Rotskoff, M.D., an oralmaxillofacial surgeon/facial cosmetic surgeon in St. Louis and Idea Forum member, said, "The purpose of the Idea Forum is to make superior products based on professional experience. As a physician, I rarely have the opportunity to help develop new medical products, yet through the Idea Forum I take feedback I receive from patients directly to the company and the improvements may be implemented."

Bruce Sher, president of Mergenet Solutions, when asked said, "We at Mergenet Solutions and Innomed Technologies are overwhelmed by the input and prestige bestowed on us by such an esteemed medical advisory board."

Innomed Technologies, Inc.

Innomed Technologies, Inc. is a 21st Century medical technologies company. The company is poised to bring new and more effective medical products and devices to the public through a medical development and engineering team, as well as acquisitions of other medical related companies. Innomed Technologies, Inc. has primarily been a research oriented, privately held, medical technology development company for the past four years. The company owns a full utility patent and patents pending. More information regarding Innomed Technologies is available at http://www.innomedinc.com.

Mergenet Solutions, Inc.

Innomed's parent company is Mergenet Solutions, Inc., a full service technology incubator based in Boca Raton, Florida. The company also can assist private companies in their efforts to become public, as well as ancillary services, such as providing a board of directors, constructing company advisory boards, private placements, etc.

A Private Securities Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in written statements to be made) contain statements that are forward-looking, such as those relating to consummation of the transaction, anticipated future revenue of the Company's, and success of current public offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward looking statements.

For more information contact: Bruce Sher or Shara Hernandez (561-558-0129)